ArticleFrontiers in immunology2026
Case Report: A case of anti-mGluR1 antibody-associated encephalitis treated with efgartigimod combined with rituximab.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-metabotropic glutamate receptor 1 (mGluR1) encephalitis is a rare autoimmune disorder affecting both the central and peripheral nervous systems, typically characterized by a subacute cerebellar syndrome. Its effective treatment remains undefined. Here, we present the case of a 16-year-old male student who experienced dizziness upon walking and standing. Symptoms gradually worsened, leading to psychiatric and behavioral abnormalities. Neurological examination revealed somnolence, dysarthria, a broad-based unsteady gait, a prominent head tremor, and limb ataxia. The first magnetic resonance imaging scan showed no obvious abnormality. The background rhythm on the electroencephalogram was normal, with no epileptiform discharges observed. A whole-body PET/CT scan revealed a mild reduction in glucose metabolism in the left frontal and temporal lobes. Lumbar puncture showed normal cerebrospinal fluid pressure but elevated white blood cell count and protein level. The diagnosis of anti-mGluR1 encephalitis was confirmed by positive anti-mGluR antibody testing, specifically showing an anti-mGluR1-IgG titer of 1:1000 in the cerebrospinal fluid and an anti-mGluR1-IgG1 titer of 10,000 in the serum. The patient did not respond to first-line therapy with corticosteroids. During disease progression, innovative sequential therapy with efgartigimod, an FcRn antagonist, was followed by the anti-CD20 monoclonal antibody rituximab (RTX) to reduce the risk of profound B-cell depletion. The patient exhibited significant clinical improvement, evidenced by a reduction in the Modified Rankin Scale (mRS) score from 4 to 3 and a decrease in the Scale for Assessment of Ataxia (SARA) score from 40 to 13. Efgartigimod effectively cleared pathogenic IgG, whereas RTX induced rapid B-cell depletion to prevent disease recurrence, thereby demonstrating synergistic efficacy. At the 12-month follow-up, the patient's clinical symptoms continued to improve, with no observed relapse. This case report underscores the importance of early diagnosis and therapeutic intervention, highlighting the need to suspect this condition based on its characteristic clinical presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.